Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium phosphopentobarbital
- Development stage
- Phase 4
- Lead developer
- Renmin Hospital of Wuhan University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Sodium phosphopentobarbital is a water-soluble prodrug that is metabolized by alkaline phosphatase into its active form, propofol. Propofol is a sedative-hypnotic agent that enhances the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system. This prodrug formulation aims to overcome the limitations of propofol's traditional lipid emulsion, such as injection pain and adverse reactions related to lipid metabolism. It is used for sedation during diagnostic or therapeutic procedures, such as endoscopy, and for the induction of general anesthesia. It is considered a Class 1 innovative drug in China.
- Brand names
- Lusedra磷丙芬
- Other names
- Fospropofol Disodium磷丙泊酚二钠磷丙泊酚
02
Targets
GABRR (GABA-A receptor subunit rho)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on sodium phosphopentobarbital.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium phosphopentobarbital.